We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BARICITINIB: THE FIRST JANUS KINASE INHIBITOR FOR THE TREATMENT OF PATIENTS WITH ATOPIC ECZEMA.
- Authors
Tucker, Rod
- Abstract
Baricitinib -- a drug previously used to treat rheumatoid arthritis - was approved by the EMA for the management of moderate to severe atopic dermatitis in adult patients in September 2020. With a UK licence revision due soon, this article reviews the clinical efficacy data for the drug when used in the treatment of patients with atopic dermatitis.
- Subjects
THERAPEUTIC use of monoclonal antibodies; ATOPIC dermatitis; CYTOKINES; NEUROTRANSMITTER uptake inhibitors; PATIENT safety; DRUG approval; JANUS kinases; PHARMACODYNAMICS; PHARMACOKINETICS
- Publication
Dermatological Nursing, 2020, Vol 19, Issue 4, p45
- ISSN
1477-3368
- Publication type
Article